Garrett Moraski

Office: Room 347

Lab: Room 346

Chemistry and Biochemistry Building
P.O. Box 173400
Bozeman, MT 59717

Phone: 406-994-3563

Fax: 406-994-3744


Research Group Website

Research Summary


  • B.S. 1997 University of Notre Dame, Notre Dame, IN

Awards and Professional Activities

  • Pfizer, 1997 – 2000
  • Array BioPharma, 2000 - 2001
  • Thios Pharmaceuticals, 2001 - 2004
  • University of Notre Dame, 2004-2012
  • SRI International, 2012-2013
  • 2012 Presidential Achievement Award, University of Notre Dame

Moraski Research Overview

I am a medicinal chemistry with a broad experience working within the pharmaceutical industry, academics and non-profit sectors. I am currently working on infectious disease targets particularly anti-tubercular agents and the development of new antibiotics. Within industry, I have had substantial experience designing anti-cancer kinase inhibitors for use in oncology (for instance, Crenolanib). Chemistry is turning negatives into positives and I hope my work will follow that arc.


Video of TB research

Video of news clip of my research "Sleep Aid Has Antituberculosis Activity"


Medicinal Chemistry, Antibacterials, Tuberculosis, Anti-cancer

Selected Publications

Putting TB to Rest: Transformation of the Sleep Aid, Ambien and ‘Anagrams’ Generated Potent Anti-tuberculosis Agents.”  Moraski, G. C.;  Miller, P. A.; Bailey, M.-A.; Ollinger, J.; Parish, T.; Boshoff, H. I.; Sanghyun, C.; Anderson, J. R.; Mulugeta, S.; Franzblau, S. G.; Miller, M. J.  ACS Infectious Diseases, 2015 1 (2), pp 85–90.  PMID: 25984566.

“Scaffold-switching: An exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.” Moraski, G. C.; Oliver, A. G.; Markley, L. D.; Cho, S.; Franzblau, S. G. Miller, M. J. Bioorg. Med. Chem. Lett. 2014, DOI: 10.1016/j.bmcl.2014.05.062.

"Bactericidal Activity of an Imidazo[1,2-a]pyridine Using a Mouse M. tuberculosis Infection Model." Cheng, Y., Moraski, G. C., Cramer, J., Miller, M. J., Schorey, J. S. PLoS One 2014, 9, No. e87483. PMID: 24498115

WO 2014015167 A2, 2014 “5,5-heteroaromatic anti-infective compounds” Inventors: Marvin J. Miller, Garrett C. Moraski.

“Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.” Moraski G. C., Markley L. D., Cramer J., Hipskind P. A., Boshoff H., Bailey M., Alling T., Ollinger J., Parish T., Miller M. J. ACS Med Chem Lett. 2013, 4, 675-679. PMID: 23930153.

“A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis.” Ollinger J., Bailey M. A., Moraski G .C., Casey A., Florio S., Alling T., Miller M. J., Parish T. PLoS One, 2013, 8, e60531. PMID: 23593234.

"Thiolates Chemically Induce Redox Activation of BTZ043 and Related Potent Nitro Aromatic Anti-Tuberculosis Agents," Tiwari, R.; Moraski, G. C.; Krchnak, V.; Miller, P.; Möllmann, U.; Colon-Martinez, M.; Herrero, E.; Oliver, A.; Miller, M. J. J. Am. Chem. Soc., 2013, 135, 3539 – 3549. PMID: 23402278.

“Anti-bacterial agents from benzo(d)heterocyclic scaffolds - useful for the prevention and treatment of multidrug resistant bacteria.” USPTO patent 8,362,268, issue date 1/29/13.

“Allylic thiocyanates as a new class of antitubercular agents,” Silveira, G. P.; Ferreira, M.; Fernandes, L.; Moraski, G. C.; Cho S.; Hwang, C.; Franzblau, S. G.; Så, M. M. Bioorg. Med. Chem. Lett. 2012, 20, 6486 – 6489. PMID: 22967767.

“Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds,” Garrett C. Moraski, Lowell D. Markley, Mayland Chang, Sanghyun Cho, Scott G. Franzblau, Chang Hwa Hwang, Helena Boshoff, and Marvin J. Miller, Bioorgan. Med. Chem., 2012, 7, 2214- 2220. PMID: 22391032

“One Step Syntheses of Nitrofuranyl Benzimidazoles that are Active Against Multi-Drug Resistant Bacteria,” Garrett C. Moraski, Jane A. Thanassi, Steven D. Podos, Michael J. Pucci and Marvin J. Miller, J. Antibiotics, 2011, 1- 5. PMID: 21811261

WO 2011/057145 A2, 2011. “IMIDAZO[1,2-a]PYRIDINE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME” Inventors: Marvin J. Miller, Garrett C. Moraski, Lowell Markley, George Davis.

“Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity,” Garrett C. Moraski, Lowell D. Markley , Philip A. Hipskind, Helena Boshoff, Sanghyun Cho, Scott G. Franzblau and Marvin J. Miller, Med. Chem. Lett., 2011, 6, 466-470. PMID: 21691438

“Design, Synthesis, and Study of a Mycobactin-Artemisinin Conjugate That Has Selective and Potent Activity against Tuberculosis and Malaria,” Marvin J Miller, Andrew J Walz, Helen Zhu, Chunrui Wu, Garrett Moraski, Ute Möllmann, Esther M Tristani, Alvin L Crumbliss, Michael T Ferdig, Lisa Checkley, Rachel L Edwards and Helena I Boshoff, J. Am. Chem. Soc., 2011, 33, 2076-9. PMID: 21275374

International Patent Application, November 3, 2010 and Provisional Patent Application No. 61/258,549, filed November 6, 2009, entitled “IMIDAZO[1,2-a]PYRIDINE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME” Inventors: Marvin J. Miller, Garrett C. Moraski, Lowell Markley, George Davis.

“N-((1-Benzyl-1H-1,2,3-triazol-4-yl)methyl)arylamide as a New Scaffold that Provides Rapid Access to Antimicrotubule Agents: Synthesis and Evaluation of Antiproliferative Activity Against Select Cancer Cell Lines,” Jonathan A Stefely, Rahul Palchaudhuri, Patricia A Miller, Rebecca J Peterson, Garrett C Moraski, Paul J Hergenrother and Marvin J Miller, J. Med. Chem, 2010, 53, 3389-95. PMID: 20334421